Cleveland Clinic appoints department chair
Click Here to Manage Email Alerts
Jae Jung, PhD, has been appointed chair of Cleveland Clinic Lerner Research Institute’s department of cancer biology.
Jung will oversee the department’s work to improve understanding of the biological underpinnings of cancer, including disease manifestation and genetic or molecular pathways.
He also will serve as director of the new Center for Global and Emerging Pathogens Research. Center staff will focus on various public health threats such as SARS-CoV-2 — which causes COVID-19 — and Zika virus.
“Jae Jung is a brilliant and global leader in research into the deep and complex intersections between the immune system and cancer,” Serpil Erzurum, MD, chair of Lerner Research Institute, said in a press release. “His work has defined how viruses induce cancers, which make up to 25% of cancers in the world. It is quite fortuitous at this time that we have recruited a world-class scientist in cancer and virus research.”
Jung is known for his expertise in virology and virus-induced cancers, including Kaposi sarcoma.
He has made key contributions to the fields of immune-oncology, inflammation and emerging pathogens. He developed one of the first preclinical models to study SARS-CoV-2 infection and transmission.
Jung previously served as chair of molecular microbiology and immunology at University of Southern California. He also served as director of USC Institute of Emerging Pathogens and Immune Diseases.
“Jae Jung is a foremost authority in virus-related cancer and immunology who will build and grow our research programs to advance science and ultimately improve care for our patients,” Brian Bolwell, MD, chairman of Taussig Cancer Institute and Cleveland Clinic Cancer Center, said in the release. “He will bring together a team of experts to better understand the complexities of these cancers and emerging pathogens to develop critically needed treatments and vaccines.”
Read more about
Click Here to Manage Email Alerts